Copertina

Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016)

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Peng Xu, Wen Luo, Jingjing Hu, Xiaobin Ma, Qian Hao, Wentao Hui, Zhangjian Zhou, Shuai Lin, Meng Wang, Hao Wu, Zhijun Dai, Huafeng Kang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Cancer Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
di: Yun Wu, et al.
Pubblicazione: (2024)

Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
di: Jasmine S. Sukumar, et al.
Pubblicazione: (2024)

Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry
di: Marc Thill, et al.
Pubblicazione: (2024)

Worse health quality outcomes found with endocrine therapy after breast‐conserving surgery
di: Mary Beth Nierengarten
Pubblicazione: (2025)

Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
di: Mauricio Rodríguez
Pubblicazione: (2023)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
di: Xudong Zhang, et al.
Pubblicazione: (2024)

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long‐term outcomes of surgery first versus neoadjuvant chemotherapy in a real‐world setting
di: Bowen Liu, et al.
Pubblicazione: (2024)

The evolution and prognostic impact of HER2‐low, HER2‐ultralow, and HER2‐null status in HER2‐negative early breast cancer: A pre– to post–neoadjuvant chemotherapy study
di: Yibin Qiu, et al.
Pubblicazione: (2026)

Real‐world progression‐free survival and overall survival in patients with HR + / HER2 − advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study
di: Peter A. Fasching, et al.
Pubblicazione: (2026)

Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
di: Akshara Singareeka Raghavendra, et al.
Pubblicazione: (2026)

Switching to camizestrant prolonged PFS for patients with ER‐positive, HER2‐negative advanced breast cancer
di: Leah Lawrence
Pubblicazione: (2025)

Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
di: Zhimin Shao, et al.
Pubblicazione: (2024)

Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early‐stage breast cancer: An Australian institutional real‐world experience
di: Sathya Narayanan, et al.
Pubblicazione: (2024)

Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
Pubblicazione: (2024)

Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study
di: Layla Andour, et al.
Pubblicazione: (2025)

Long‐term outcomes and risk profile of cT3N0 breast cancer treated with neoadjuvant chemotherapy and curative surgery
di: Young Seob Shin, et al.
Pubblicazione: (2024)

Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
di: Xu Liang, et al.
Pubblicazione: (2024)

Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy
di: Andrew H S Lee, et al.
Pubblicazione: (2025)

Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor‐positive breast cancer
di: Siti Nur Hasyila Muhammad, et al.
Pubblicazione: (2026)

An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
di: Jefferson Antonio Buendía
Pubblicazione: (2013)

p95HER2 expression in HER2‐positive breast cancer with primary resistance
di: Chih Wan Goh, et al.
Pubblicazione: (2024)

HER2‐positive grade 1 invasive carcinomas of the breast
di: Andrew H S Lee, et al.
Pubblicazione: (2024)

Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry
di: Patrick Marschner, et al.
Pubblicazione: (2026)

Combination of Lenvatinib and pembrolizumab as neoadjuvant treatment for BRAF negative anaplastic thyroid cancer
di: Zhao Jie, et al.
Pubblicazione: (2025)

Palbociclib in breast cancer neoadjuvant setting
di: Sílvia Alexandra Cabral Duarte
Pubblicazione: (2021)

Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial
di: Xiaochu Man, et al.
Pubblicazione: (2024)

Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis
di: Lixi Li, et al.
Pubblicazione: (2024)

Neoadjuvant chemotherapy for resectable gastric cancer is associated with better outcomes than neoadjuvant chemoradiation
di: Hideo Takahashi, et al.
Pubblicazione: (2024)

Nottingham prognostic x (NPx): a risk stratification tool in ER‐positive HER2‐negative breast cancer: a validation study
di: Ayat G Lashen, et al.
Pubblicazione: (2024)

The survival outcomes of localized low‐risk prostate cancer, a population‐based study using NCDB
di: Shifeng Mao, et al.
Pubblicazione: (2024)

Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study
di: Eyyup Cavdar
Pubblicazione: (2022)

Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
di: Eudald Felip, et al.
Pubblicazione: (2025)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
di: Eduardo Terán, et al.
Pubblicazione: (2024)

Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study
di: Xuelian Wang, et al.
Pubblicazione: (2024)

Effects of presurgical HIIT in hormone receptor‐positive, HER 2‐negative breast cancer cases: Two case reports from the GEICAM EFiK study
di: Txomin Pérez‐Bilbao, et al.
Pubblicazione: (2025)

Real world study of pertuzumab-trastuzumab-chemotherapy versus trastuzumab-chemotherapy in neoadjuvant treatment of breast cancer
di: Rocío Díaz-Acedo
Pubblicazione: (2020)

Assessment of textbook oncologic outcome after neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer
di: Jiayin Yu, et al.
Pubblicazione: (2025)

Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer
di: Yuhan Wei, et al.
Pubblicazione: (2025)

A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer
di: Kathy D. Miller, et al.
Pubblicazione: (2026)

A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
di: Xinpei Deng, et al.
Pubblicazione: (2024)